دورية أكاديمية
أعرض في EDS

Cordycepin- melittin nanoconjugate intensifies wound healing efficacy in diabetic rats.

التفاصيل البيبلوغرافية
العنوان: Cordycepin- melittin nanoconjugate intensifies wound healing efficacy in diabetic rats.
المؤلفون: Shaik RA; Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Alotaibi MF; Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.; Althager General Hospital, Jeddah, Ministry of Health, Saudi Arabia., Nasrullah MZ; Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Alrabia MW; Department of Microbiology and Medical Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Asfour HZ; Department of Microbiology and Medical Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Abdel-Naim AB; Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
المصدر: Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society [Saudi Pharm J] 2023 May; Vol. 31 (5), pp. 736-745. Date of Electronic Publication: 2023 Mar 27.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Saudi Pharmaceutical Society Country of Publication: Saudi Arabia NLM ID: 9705695 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1319-0164 (Print) Linking ISSN: 13190164 NLM ISO Abbreviation: Saudi Pharm J Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: Riyadh : Saudi Pharmaceutical Society
Original Publication: Riyadh, Kingdom of Saudi Arabia : The Society,
مستخلص: The current study was designed to develop a nanoconjugate of cordycepin-melittin (COR-MEL) and assess its healing property in wounded diabetic rats. The prepared nanoconjugate has a particle size of 253.5 ± 17.4 nm with a polydispersity index (PDI) of 0.35 ± 0.04 and zeta potential of 17.2 ± 0.3 mV. To establish the wound healing property of the COR-MEL nanoconjugate, animal studies were pursued, where the animals with diabetes were exposed to excision and treated with COR hydrogel, MEL hydrogel, or COR-MEL nanoconjugate topically. The study demonstrated an accelerated wound contraction in COR-MEL nanoconjugate -treated diabetic rats, which was further validated by histological analysis. The nanoconjugate further exhibited antioxidant activities by inhibiting the accumulation of malondialdehyde (MDA) and exhaustion of superoxide dismutase (SOD) and glutathione peroxidase (GPx) enzymatic activities. The nanoconjugate further demonstrated an enhanced anti-inflammatory activity by retarding the expression of interleukin (IL)-6 and tumor necrosis factor (TNF)-α. Additionally, the nanoconjugate exhibits a strong expression of transforming growth factor (TGF)-β1, vascular endothelial growth factor (VEGF)-A, and platelet-derived growth factor (PDGFR)-β, indicating enrichment of proliferation. Likewise, nanoconjugate increased the concentration of hydroxyproline as well as the mRNA expression of collagen, type I, alpha 1 (Col 1A1). Thus, it is concluded that the nanoconjugate possesses a potent wound-healing activity in diabetic rats via antioxidant, anti-inflammatory, and pro-angiogenetic mechanisms.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2023 The Author(s).)
References: Wound Repair Regen. 2009 Jul-Aug;17(4):461-72. (PMID: 19614910)
Pharmaceutics. 2021 Jun 29;13(7):. (PMID: 34209654)
Mediators Inflamm. 2017;2017:3946706. (PMID: 28522898)
Int J Mol Sci. 2017 Jul 03;18(7):. (PMID: 28671607)
Sci Transl Med. 2021 Mar 17;13(585):. (PMID: 33731435)
Antioxidants (Basel). 2018 Jul 24;7(8):. (PMID: 30042332)
Life (Basel). 2022 Jul 21;12(7):. (PMID: 35888184)
Int Immunopharmacol. 2018 Jul;60:18-25. (PMID: 29702279)
Pharmacol Res. 2008 Aug;58(2):165-71. (PMID: 18617006)
Expert Opin Drug Deliv. 2014 Jul;11(7):1005-13. (PMID: 24702435)
Life Sci. 2019 Apr 15;223:120-127. (PMID: 30790609)
Eur J Pharmacol. 2013 Jan 30;700(1-3):165-72. (PMID: 23220163)
Wound Repair Regen. 2021 Jul;29(4):573-581. (PMID: 34157786)
BMC Vet Res. 2017 Feb 21;13(1):60. (PMID: 28222732)
Int J Clin Pharmacol Ther. 2004 Jul;42(7):353-9. (PMID: 15605686)
Int J Mol Sci. 2019 Nov 28;20(23):. (PMID: 31795299)
Br J Dermatol. 2015 Aug;173(2):370-8. (PMID: 26175283)
Biomaterials. 2022 Apr;283:121465. (PMID: 35286850)
J Surg Res. 2009 May 15;153(2):347-58. (PMID: 19027922)
Molecules. 2020 Jun 12;25(12):. (PMID: 32545666)
Biomed Chromatogr. 2008 Jun;22(6):630-6. (PMID: 18254139)
Drug Deliv. 2022 Dec;29(1):1892-1902. (PMID: 35748413)
Am J Pathol. 2006 Dec;169(6):2254-65. (PMID: 17148686)
Front Pharmacol. 2021 May 28;12:704503. (PMID: 34122120)
Pharmacol Res. 2022 Jan;175:105993. (PMID: 34801680)
Molecules. 2020 Dec 31;26(1):. (PMID: 33396220)
Exp Biol Med (Maywood). 2011 Nov;236(11):1306-13. (PMID: 21969711)
Nutr Res. 2015 May;35(5):431-9. (PMID: 25940982)
Front Pharmacol. 2021 Feb 03;11:642171. (PMID: 33633571)
Clin Cosmet Investig Dermatol. 2017 Jul 13;10:259-265. (PMID: 28761364)
Int J Mol Sci. 2021 May 25;22(11):. (PMID: 34070360)
Ann Anat. 2019 Mar;222:94-102. (PMID: 30521949)
Endocr Metab Immune Disord Drug Targets. ;17(2):87 - 95. (PMID: 28427246)
Pharmacol Rev. 2016 Jul;68(3):701-87. (PMID: 27363439)
BMC Complement Altern Med. 2014 Aug 05;14:286. (PMID: 25091565)
J Vet Med Sci. 2005 Jan;67(1):111-4. (PMID: 15699606)
Foods. 2021 Oct 30;10(11):. (PMID: 34828915)
Oxid Med Cell Longev. 2021 Jan 4;2021:8843051. (PMID: 33488946)
Bioengineering (Basel). 2021 May 11;8(5):. (PMID: 34064689)
Int J Nanomedicine. 2020 Dec 03;15:9717-9743. (PMID: 33299313)
PLoS One. 2014 Mar 20;9(3):e92667. (PMID: 24651576)
Oncotarget. 2015 Nov 3;6(34):35496-508. (PMID: 26462178)
J Dent Res. 2010 Mar;89(3):219-29. (PMID: 20139336)
Mol Biol (Mosk). 2019 Sep-Oct;53(5):741-754. (PMID: 31661475)
Asia Pac J Clin Nutr. 2002;11 Suppl 7:S448-51. (PMID: 12492633)
Stem Cell Res Ther. 2020 Jun 11;11(1):232. (PMID: 32527289)
Front Microbiol. 2019 Jun 20;10:1348. (PMID: 31293530)
Bioact Mater. 2022 Jul 01;20:561-573. (PMID: 35846841)
Drug Des Devel Ther. 2014 Oct 16;8:1941-53. (PMID: 25342887)
Pharmaceutics. 2021 Oct 06;13(10):. (PMID: 34683915)
Philos Trans R Soc Lond B Biol Sci. 2004 May 29;359(1445):839-50. (PMID: 15293811)
Prog Histochem Cytochem. 2007;42(3):115-70. (PMID: 17980716)
Pharmaceutics. 2020 Apr 11;12(4):. (PMID: 32290412)
فهرسة مساهمة: Keywords: Cordycepin; Diabetic wounds; Melittin; Nanoconjugate; Wound healing
تواريخ الأحداث: Date Created: 20230514 Latest Revision: 20230516
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10172630
DOI: 10.1016/j.jsps.2023.03.014
PMID: 37181143
قاعدة البيانات: MEDLINE
الوصف
تدمد:1319-0164
DOI:10.1016/j.jsps.2023.03.014